Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BTAI
BTAI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BTAI News
BioXcel to Host Virtual Event on April 23 to Discuss Launch Strategy for IGALMI
3d ago
Newsfilter
Investigation into BioXcel Therapeutics' Corporate Governance Breaches
Apr 10 2026
PRnewswire
BioXcel Initiates Phase 2a Study for Acute Stress Reactions
Apr 08 2026
NASDAQ.COM
BioXcel Initiates Clinical Trial for ASR Treatment
Apr 08 2026
Newsfilter
BioXcel Submits sNDA for IGALMI® in At-Home Treatment
Mar 27 2026
Newsfilter
BioXcel Therapeutics Q4 Earnings Beat Expectations
Mar 27 2026
seekingalpha
BioXcel Therapeutics Enters Securities Purchase Agreement for $8 Million Offering
Mar 10 2026
Newsfilter
BioXcel Therapeutics Shares Decline Despite Positive Drug Development News
Mar 06 2026
Benzinga
BIOXCEL THERAPEUTICS STOCK INCREASES 2.7% FOLLOWING POSITIVE RESULTS FROM MID-STAGE TRIAL OF EXPERIMENTAL OPIOID WITHDRAWAL TREATMENT
Mar 05 2026
moomoo
BioXcel Therapeutics Reports Positive Phase 2 Results for Opioid Withdrawal Treatment
Mar 05 2026
Benzinga
BioXcel Therapeutics Reports Positive Phase 2 Trial Results for Opioid Withdrawal Treatment
Mar 05 2026
stocktwits
Halper Sadeh Investigates BioXcel Therapeutics for Potential Breach of Fiduciary Duties
Jan 15 2026
Businesswire
BioXcel Seeks FDA Approval for At-Home Use of IGALMI® in Agitation Treatment
Jan 09 2026
Newsfilter
BioXcel Seeks FDA Approval for At-Home Use of IGALMI in Agitation Treatment
Jan 07 2026
NASDAQ.COM
BioXcel Therapeutics Hosts Virtual Roundtable on Self-Administered Treatment Opportunities
Dec 03 2025
Globenewswire
BioXcel Hosts Roundtable on Self-Administered Treatments for 77M Agitation Episodes
Dec 03 2025
Newsfilter
Show More News
